TransMedics Group, Inc.
As of Oct 22, 2026, TransMedics Group is in Stage 1, the basing phase, now in week 11 (since Aug 7, 2026). It closed at $72.06, 52.1% below its 52-week high and below its 200-day average, which is falling.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is TMDX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
TMDX among Medical Devices81st of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …81 | TMDX | Stage 1 · wk 11 | 28 | −17.2% |
TransMedics Group: quick answers
What stage is TransMedics Group in?
As of Oct 22, 2026, TransMedics Group (TMDX) is in Stage 1, the basing phase. It entered Stage 1 on Aug 7, 2026 and is in week 11. What the four stages mean
Is TransMedics Group in an uptrend?
Not yet. TransMedics Group is in Stage 1, a base that can come before an uptrend. It trades 25.4% below its 200-day average, which is falling.
How far is TransMedics Group from its 52-week high?
TransMedics Group closed at $72.06 on Oct 22, 2026, 52.1% below its 52-week high of $150.42. Its 52-week low is $62.04.
How has TransMedics Group performed over the past year?
As of Oct 22, 2026, TransMedics Group is down 40.0% over the past year and down 41.3% so far in 2026.
Which sector and industry is TransMedics Group in?
TransMedics Group is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.